Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.
Founded
2011
Raised
$98.1M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$50,500,000
Venture capital (Series C) - 2017
NEA Omega Funds TPG Biotechnology Partners +2
$15,000,000
Debt financing - 2015
Square 1 Bank Solar capital
Team Size
2
Employees
$50,500,000 Venture capital (Series C)
PE HUB

NEA leads $50.5 mln Series C round in Trevi Therapeutics

Health Funding Science
$15,000,000 Debt financing
abladvisor

Solar Capital, Square 1 Bank Provide $15MM Facility to Trevi Therapeutics - News | ABL Advisor